CD34 and familial dilated cardiomyopathy: Fifty-five patients with DCM with LVEF <30% and NYHA class III were randomly assigned to 28 patients who received an intracoronary injection of CD34+ cells (the cell treatment group) or 27 patients who did not receive cell therapy (the control group).